Emerging roles for antiangiogenesis factors in management of ocular disease

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 533-543

  Saeed, Muhammad Usman ^a   Gkaragkani, Evangelia ^a   Ali, Kashif ^b  

^a EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b Countess of Chester Hospital NHS Foundation Trust ^*  (United Kingdom)

Author keywords

Afibercept; Bevacizumab; Indications; Pegaptanib; Ranibizumab; Retina

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; DEXAMETHASONE; PEGAPTANIB; PLACEBO; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN INHIBITOR; VERTEPORFIN;

ANTIANGIOGENIC ACTIVITY; BASAL CELL CARCINOMA; BLOOD VESSEL PERMEABILITY; BRANCH RETINAL VEIN OCCLUSION; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CENTRAL SEROUS RETINOPATHY; CHOROID TUMOR; CHOROIDAL HEMANGIOMA; CLINICAL PRACTICE; COLON CARCINOMA; COLON TUMOR; CORNEA NEOVASCULARIZATION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG CONTAMINATION; DRUG COST; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; ECONOMIC ASPECT; ENDOPHTHALMITIS; EVIDENCE BASED PRACTICE; EXUDATIVE MACULAR DEGENERATION; EYE DISEASE; EYE INFECTION; EYE TUMOR; HEALTH CARE PLANNING; HEMANGIOMA; HUMAN; INTRAOCULAR PRESSURE; IRIS NEOVASCULARIZATION; LASER COAGULATION; LOADING DRUG DOSE; LOW DRUG DOSE; LOW LEVEL LASER THERAPY; LUNG SMALL CELL CANCER; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEOVASCULAR GLAUCOMA; OPTIC NERVE DISEASE; PERIOCULAR BASAL CELL CARCINOMAS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; RETINA MACULOPATHY; RETINA VEIN OCCLUSION; RETROLENTAL FIBROPLASIA; REVIEW; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; TOXIC ANTERIOR SEGMENT LIKE SYNDROME; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY;

EID: 84875161823     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S31016     Document Type: Review

References (96)

1. Hata Y, Nakagawa K, Ishibashi T, Inomata H, Ueno H, Sueishi K. Hypoxia-induced expression of vascular endothelial growth factor by retinal glial cells promotes in vitro angiogenesis. Virchows Arch. 1995;426(5):479-486.
2. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol. 1996;80(4):363-366.
3. Frank RN, Amin RH, Eliott D, Puklin JE, Abrams G W. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol. 1996;122(3):393-403.
4. Aiello L P, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci U S A. 1995;92(23):10457-10461.
5. Ferrara N, Hillan KJ, Gerber H P, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(5):391-400.
6. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
7. Michels S, Rosenfeld PJ, Puliafto CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration; twelve-week results of an uncontrolled openlabel clinical study. Ophthalmology. 2005;112(6):1035-1047.
8. nice.org.uk [homepage on the Internet]. 'Do not do' recommendation details. Guidance TA155. London: National Institute for Health and Clinical Excellence; 2012 [updated September 14, 2012]. Available from: http://www.nice.org.uk/usingguidance/donotdorecommendations/detail.jsp?action=details&dndid=548. Accessed September 18, 2012.
9. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
10. nice.org.uk [homepage on the Internet]. Guidance on the use of photodynamic therapy for age-related macular degeneration. Technology Appraisal 68. London: National Institute for Health and Clinical Excellence; 2012 [published Sep 2003]. Available from: http:// www.nice.org.uk/nicemedia/live/11512/32728/32728.pdf. Accessed September 18, 2012.
11. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfn for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
12. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intra-vitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol. 2009;148(1):43-58.
13. CATT Research Group, Martin D F, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-1908.
14. IVAN Study Investigators, Chakravarthy U, Harding S P, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399-1411.
15. British National Formulary (BNF) 63. London: BMJ Group; RPS Publishing; 2012:720.
16. moorfieldspharmaceuticals.co.uk [webpage on the Internet]. Moorefeld's Pharmacy Price Guide 2012. London: Moorfelds Pharmaceuticals; 2012. Available from: http://www.moorfeldspharmaceuticals. co.uk/specials/ophthalmic-specials.html. Accessed September 18, 2012.
17. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol. 2008;92(12):1606-1611.
18. Sivaprasad S, Hykin P, Saeed A, et al. Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience. Eye (Lond). 2010;24(5):793-798.
19. Nishimura Y, Taguchi M, Nagai T, Fujihara M, Honda S, Uenishi M. Comparison of the effect between pegaptanib and ranibizumab on exudative age-related macular degeneration with small lesion size. Clin Ophthalmol. 2012;6:365-368.
20. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet AgeRelated Macular Degeneration. Ophthalmology. 2012;119(12): 2537-2548.
21. Heier JS, Boyer D, Nguyen QD, et al; CLEAR-IT 2 Investigators. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011;118(6):1098-1106.
22. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695. e1-e15.
23. Minella AM, Savastano CM, Ziccardi L, Scupola A, Falsini B, Balestrazzi E. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy. Acta Ophthalmol. 2008;86(6):683-687.
24. Ushida H, Kachi S, Asami T, Ishikawa K, Kondo M, Terasaki H. Infuence of preoperative intra-vitreal bevacizumab on visual function in eyes with proliferative diabetic retinopathy. Ophthalmic Res. 2013;49(1):30-36.
25. Arevalo J F, Sanchez JG, Lasave AF, et al. Intravitreal bevacizumab (Avastin) for diabetic retinopathy: The 2010 GLADAOF Lecture. J Ophthalmol. 2011:2011:584238.
26. Muqit MM, Marcellino GR, Henson DB, et al. Optos-guided pattern scan laser (Pascal)-targeted retinal photocoagulation in proliferative diabetic retinopathy. Acta Ophthalmol. Epub December 16, 2011.
27. Muqit MM, Marcellino GR, Henson DB, et al. Single-session vs multiple-session pattern scanning laser panretinal photocoagulation in proliferative diabetic retinopathy: The Manchester Pascal Study. Arch Ophthalmol. 2010;128(5):525-533.
28. Romano MR, Gibran SK, Marticorena J, Wong D, Heimann H. Can a preoperative bevacizumab injection prevent recurrent postvitrectomy diabetic vitreous haemorrhage? Eye (Lond). 2009;23(8): 1698-1701.
29. Arevalo JF, Maia M, Flynn HW Jr, et al. Tractional retinal detachment following intra-vitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008;92(2):213-216.
30. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intra-vitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology. 2010;117(6):1078-1086.
31. Elman MJ, Bressler NM, Qin H, et al; Diabetic Retinopathy Clinical Research Network. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118(4):609-614.
32. Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119(11):2312-2318.
33. Diabetic Retinopathy Clinical Research Network, Googe J, Brucker AJ, et al. Randomized trial evaluating short-term effects of intra-vitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31(6):1009-1027.
34. Soheilian M, Ramezani A, Bijanzadeh B, et al. Intravitreal bevacizumab (Avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina. 2007;27(9):1187-1195.
35. Sheth S, Rush R, Natarajan S, Gillies M. Intravitreal triamcinolone acetonide versus combined intra-vitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema. Clin Experiment Ophthalmol. 2011;39(7):673-681.
36. Faghihi H, Roohipoor R, Mohammadi, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol. 2008;18(6):941-948.
37. nice.org.uk.[homepage on the Internet].'Do not do' recommendation details. Guidance TA237. London: National Institute for Health and Clinical Excellence; 2012 [updated September 14, 2012]. Available from: http://www.nice.org.uk/usingguidance/donotdorecommendations/detail.jsp?action=details&dndid=1034. Accessed December 3, 2012.
38. Ip MS, Domalpally A, Hopkins JJ, Wong P, Ehrlich JS. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol. 2012;130(9):1145-1152.
39. Do DV, Nguyen QD, Boyer D, et al; DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology. 2012;119(8):1658-1665.
40. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intra-vitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147(2):298-306.
41. Brown DM, Campochiaro PA, Singh R P, et al; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmolog y. 2010;117(6):1124-1133.
42. Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol. 2010;150(3):310-314.
43. Scott IU, Ip MS, VanVeldhuisen PC, et al; SCORE Study Research Group.A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115-1128.
44. Ding X, Li J, Hu X, Yu S, Pan J, Tang S. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina. 2011;31(5):838-845.
45. Kim JY, Park S P. Comparison between intravitreal bevacizumab and triamcinolone for macular edema secondary to branch retinal vein occlusion. Korean J Ophthalmol. 2009;23(4):259-265.
46. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-1032.
47. Duch S, Buchacra O, Milla E, Andreu D, Tellez J. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma. 2009;18(2):140-143.
48. Wakabayashi T, Oshima Y, Sakaguchi H, et al. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008;115(9):1571-1580.
49. Ciftci S, Sakalar YB, Unlu K, Keklikci U, Caca I, Dogan E. Intravitreal bevacizumab combined with panretinal photocoagulation in the treatment of open angle neovascular glaucoma. Eur J Ophthalmol. 2009;19(6):1028-1033.
50. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmolog y. 2006;113(10):1695. e1-e15.
51. Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M. Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma. 2009;18(8):632-637.
52. Chen CH, Lai IC, Wu PC, et al. Adjunctive intravitreal bevacizumabcombined trabeculectomy versus trabeculectomy alone in the treatment of neovascular glaucoma. J Ocul Pharmacol Ther. 2010;26(1):111-118.
53. Marey HM, Ellakwa AF. Intravitreal bevacizumab with or without mitomycin C trabeculectomy in the treatment of neovascular glaucoma. Clin Ophthalmol. 2011;5:841-845.
54. Amselem L, Montero J, Diaz-Llopis M, et al. Intravitreal bevacizumab (Avastin) injection in ocular ischemic syndrome. Am J Ophthalmol. 2007;144(1):122-124.
55. Zhang H, Liu ZL, Sun P, Gu F. Intravitreal bevacizumab as primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy: results of a 1-year prospective trial. Retina. 2012;32(6):1106-1113.
56. Julián K, Terrada C, Fardeau C, et al. Intravitreal bevacizumab as first local treatment for uveitis-related choroidal neovascularization: longterm results. Acta Ophthalmol. 2011;89(2):179-184.
57. Mansour AM, Arevalo JF, Fardeau C, et al. Three-year visual and anatomic results of administrating intra-vitreal bevacizumab in infammatory ocular neovascularization. Can J Ophthalmol. 2012;47(3):269-274.
58. De Benedetto U, Battaglia Parodi M, Knutsson KA, et al. Intravitreal bevacizumab for extrafoveal choroidal neovascularization after ocular trauma. J Ocul Pharmacol Ther. 2012;28(5):550-552.
59. Qureshi F, Saeed MU, Kamal A. Primary intra-vitreal ranibizumab for myopic choroidial neovascularisation. Semin Ophthalmol. 2011; 26(2):52-54.
60. Chang JH, Garg NK, Lunde E, Han K Y, Jain S, Azar DT. Corneal Neovascularization: An Anti-VEGF Therapy Review. Surv Ophthalmol. 2012;57(5):415-429.
61. Benayoun Y, Adenis J P, Casse G, Forte R, Robert PY. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study. Cornea. 2012;31(8):937-944.
62. Yeung SN, Lichtinger A, Kim P, Amiran MD, Slomovic AR. Combined use of sub-conjunctival and intracorneal bevacizumab injection for corneal neovascularization. Cornea. 2011;30(10):1110-1114.
63. You IC, Im SK, Lee SH, Yoon KC. Photodynamic therapy with verteporfn combined with sub-conjunctival injection of bevacizumab for corneal neovascularization. Cornea. 2011;30(1):30-33.
64. Qian CX, Bahar I, Levinger E, Rootman D. Combined use of superfcial keratectomy and sub-conjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27(9):1090-1092.
65. Anijeet DR, Zheng Y, Tey A, Hodson M, Sueke H, Kaye SB. Imaging and evaluation of corneal vascularization using fuorescein and indocyanine green angiography. Invest Ophthalmol Vis Sci. 2012;53(2): 650-658.
66. Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C. Shortand long-term safety profle and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2009;247(10):1375-1382.
67. Tuncer S, Demirci H, Shields CL, Shields JA. Polypoidal choroidal vasculopathy following photodynamic therapy for choroidal haemangioma. Eur J Ophthalmol. 2009;19(1):159-162.
68. Finger PT, Chin KJ. Antivascular endothelial growth factor bevacizumab for radiation optic neuropathy: secondary to plaque radiotherapy. Int J Radiat Oncol Biol Phys. 2012;82(2):789-798.
69. Mason JO 3rd, Albert MA Jr, Persaud TO, Vail RS. Intravitreal bevacizumab treatment for radiation macular edema after plaque radiotherapy for choroidal melanoma. Retina. 2007;27(7):903-937.
70. Finger PT. Radiation retinopathy is treatable with anti-vascular endothelial growth factor bevacizumab (Avastin). Int J Radiation Oncology Biol Phys. 2008;70(4):974-977.
71. Brar VS, Sharma RK, Keshavamurthy R, Chalam K V. Vascular endothelial growth factor protects against oxidative stress in differentiated retinal ganglion cells. IOVS. 2009:50E abstract 4443.
72. Kuo IC, Haller JA, Maffrand R, Sambauelli RH, Reviglio VE. Regression of a subfoveal choroidal metastaisis of colorectal carcinoma after intravitreous bevacizumab treatment. Arch Ophthalmol. 2008;126(9):1311-1313.
73. el Filali M, Ly LV, Luyten G P, et al. Bevacizumab and intraocular tumors: an intriguing paradox. Mol Vis. 2012;18:2454-2467.
74. Kenawy N, Groenewald C P, Damato B. Treatment of vasoproliferative tumour with intra-vitreal bevazcizumab (Avastin). Eye (Lond). 2007; 21(6):893-894.
75. Rennie IG. Retinal vasoproliferaive tumours. Eye (Lond). 2010; 24(3):468-471.
76. Biancitto C, Shields CL, Kang B, Shields JA. Treatment of iris melanoma and secondary neovascular glaucoma using bevacizumab and plaque radiotherapy. Arch Ophthalmol. 2008;126(4):578-579.
77. Papastenanou V P, Cohen VML. Ciliary body adenoma of the non-pigmented epithelium with rubeosis irides treated with plaque brachytherapy and Bevazicumab. Eye (Lond). 2012;26(10):1388-1390.
78. Töteberg-Harms M, Kurz-Levin M, Fleischhauer J, Windisch R. Experiences with chronic central serous chorioretinopathy treated with half-dose photodynamic therapy and verteporfn. Ophthalmologe. 2011;108(10):947-951. German.
79. Fujita K, Yuzawa M, Mori R. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results. Retina. 2011;31(4):772-778.
80. Peyman GA, Tsipursky M, Nassiri N, Conway M. Oscillatory photodynamic therapy for choroidal neovascularization and central serous retinopathy; a pilot study. J Ophthalmic Vis Res. 2011;6(3): 166-176.
81. Uetani R, Ito Y, Oiwa K, Ishikawa K, Terasaki H. Half-dose vs one-thirddose photodynamic therapy for chronic central serous chorioretinopathy. Eye (Lond). 2012;26(5):640-649.
82. Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS. Safety enhanced therapy with half dose verteporfn for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol. 2006;90(7):869-874.
83. Seong HK, Bae JH, Kim ES, Han JR, Nam WH, Kim HK. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect. Ophthalmologica. 2009;223(5):343-347.
84. Arevalo J F, Espinoza J V. Single-session combined photodynamic therapy with verteporfn and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol. 2011;249(8):1159-1166.
85. Beger I, Koss MJ, Koch F. Treatment of central serous chorioretinopathy: micropulse photocoagulation versus bevacizumab. Ophthalmologe. 2012;109(12):1224-1232. German.
86. Semeraro F, Romano MR, Danzi P, Morescalchi F, Costagliola C. Intravitreal bevacizumab versus low-fuence photodynamic therapy for treatment of chronic central serous chorioretinopathy. Jpn J Ophthalmol. 2012;56(6):608-612.
87. G Kotoula M, Zacharaki F, E Tsironi E. Intravitreal bevacizumab for photodynamic therapy-induced massive macular detachment in acute central serous chorioretinopathy. Case Report Ophthalmol. 2012;3(2):196-199.
88. Entezari M, Ramezani A, Yaseri M. Intravitreal bevacizumab for treatment of refractory central serous choroidoretinopathy. Korean J Ophthalmol. 2012;26(2):139-142.
89. Qureshi F, Dewhurst C, Yoxall C W, Clark D. Rescue intra-vitreal Bevazicumab for aggressive posterior retinopathy of prematurity. Semin Ophthal. 2011;26(2):55-58.
90. Wu WC, Lin RI, Shih C P, et al. Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity. Ophthalmology. 2012;119(9):1907-1916.
91. Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group. Efficacy of intra-vitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011;17;364(7):603-615.
92. Hu J, Blair M P, Shapiro MJ, Lichtenstein SJ, Galasso JM, Kapur R. Reactivation of retinopathy of prematurity after bevacizumab injection. Arch Ophthalmol. 2012;130(8):1000-1006.
93. Mintz-Hittner HA. Intravitreal pegaptanib as adjunctive treatment for stage 3+ ROP shown to be effective in a prospective, randomized, controlled multicenter clinical trial. Eur J Ophthalmol. 2012; 22(5):685-686.
94. Mititelu M, Chaudhary KM, Lieberman RM. An Evidence-Based Meta-analysis of Vascular Endothelial Growth Factor Inhibition in Paediatric Retinal Diseases: Part 1. Retinopathy of Prematurity. J Pediatr Ophthalmol Strabismus. 2012:1-9.
95. Rutland CS, Mitchell CA, Nasir M, Konerding MA, Drexler HC. Microphthalmia, persistent hyperplastic hyaloid vasculature and lens anomalies following overexpression of VEGF-A188 from the alpha A-crystallin promoter. Mol Vis. 2007;13:47-56.
96. TAP study group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfn. One-year results of 2 randomised clinical trials TAP report 1. Arch Ophthalmol. 1999;117:1329-1345.